{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:43:03Z","timestamp":1763037783020,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T00:00:00Z","timestamp":1653177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T00:00:00Z","timestamp":1653177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00705-022-05466-y","type":"journal-article","created":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T07:02:21Z","timestamp":1653202941000},"page":"1669-1674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B"],"prefix":"10.1007","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8326-4930","authenticated-orcid":false,"given":"Lucio","family":"Boglione","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"De Benedetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Dodaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Chiecchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amedeo","family":"De Nicol\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"D\u2019Avolio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,22]]},"reference":[{"key":"5466_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","author":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver (2017) EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021","journal-title":"J Hepatol"},{"key":"5466_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1517\/14656566.2016.1118056","volume":"17","author":"Y-C Chen","year":"2016","unstructured":"Chen Y-C, Liaw Y-F (2016) Pharmacotherapeutic options for hepatitis B. Expert Opin Pharmacother 17:355\u2013367. https:\/\/doi.org\/10.1517\/14656566.2016.1118056","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 3","key":"5466_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3851\/IMP1624","volume":"15","author":"P Marcellin","year":"2010","unstructured":"Marcellin P, Liang J (2010) A personalized approach to optimize hepatitis B treatment in treatment-naive patients. Antivir Ther 15(Suppl 3):53\u201359. https:\/\/doi.org\/10.3851\/IMP1624","journal-title":"Antivir Ther"},{"key":"5466_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/MNH.0000000000000392","volume":"27","author":"L Chan","year":"2018","unstructured":"Chan L, Asriel B, Eaton EF, Wyatt CM (2018) Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug. Curr Opin Nephrol Hypertens 27:102\u2013112. https:\/\/doi.org\/10.1097\/MNH.0000000000000392","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"5466_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s11096-015-0132-1","volume":"37","author":"PR Quesada","year":"2015","unstructured":"Quesada PR, Esteban LL, Garc\u00eda JR et al (2015) Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients. Int J Clin Pharm 37:865\u2013872. https:\/\/doi.org\/10.1007\/s11096-015-0132-1","journal-title":"Int J Clin Pharm"},{"key":"5466_CR6","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/jac\/dku502","volume":"70","author":"P Maggi","year":"2015","unstructured":"Maggi P, Montinaro V, Leone A et al (2015) Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. J Antimicrob Chemother 70:1150\u20131154. https:\/\/doi.org\/10.1093\/jac\/dku502","journal-title":"J Antimicrob Chemother"},{"key":"5466_CR7","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK et al (2018) 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 68:672\u2013681. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.039","journal-title":"J Hepatol"},{"key":"5466_CR8","doi-asserted-by":"publisher","first-page":"175628481878610","DOI":"10.1177\/1756284818786108","volume":"11","author":"R Byrne","year":"2018","unstructured":"Byrne R, Carey I, Agarwal K (2018) Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence. Ther Adv Gastroenterol 11:1756284818786108. https:\/\/doi.org\/10.1177\/1756284818786108","journal-title":"Ther Adv Gastroenterol"},{"key":"5466_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41397-018-0064-y","volume":"19","author":"A Calcagno","year":"2019","unstructured":"Calcagno A, Fiuman\u00f2 M, Zugna D et al (2019) Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization? Pharmacogenomics J 19:65\u201371. https:\/\/doi.org\/10.1038\/s41397-018-0064-y","journal-title":"Pharmacogenomics J"},{"key":"5466_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jpba.2015.05.016","volume":"114","author":"A De Nicol\u00f2","year":"2015","unstructured":"De Nicol\u00f2 A, Simiele M, Pensi D et al (2015) UPLC-MS\/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients. J Pharm Biomed Anal 114:127\u2013132. https:\/\/doi.org\/10.1016\/j.jpba.2015.05.016","journal-title":"J Pharm Biomed Anal"},{"key":"5466_CR11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1517\/14740331003627458","volume":"9","author":"S Rodriguez-N\u00f3voa","year":"2010","unstructured":"Rodriguez-N\u00f3voa S, Alvarez E, Labarga P, Soriano V (2010) Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 9:545\u2013559. https:\/\/doi.org\/10.1517\/14740331003627458","journal-title":"Expert Opin Drug Saf"},{"key":"5466_CR12","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/ki.2010.318","volume":"78","author":"LC Herlitz","year":"2010","unstructured":"Herlitz LC, Mohan S, Stokes MB et al (2010) Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 78:1171\u20131177. https:\/\/doi.org\/10.1038\/ki.2010.318","journal-title":"Kidney Int"},{"key":"5466_CR13","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1097\/QAD.0000000000001572","volume":"31","author":"L Mili\u00e1n","year":"2017","unstructured":"Mili\u00e1n L, Peris JE, Gand\u00eda P et al (2017) Tenofovir-induced toxicity in renal proximal tubular epithelial cells: involvement of mitochondria. AIDS Lond Engl 31:1679\u20131684. https:\/\/doi.org\/10.1097\/QAD.0000000000001572","journal-title":"AIDS Lond Engl"},{"key":"5466_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.lfs.2019.03.042","volume":"224","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Yang Y, Wang P et al (2019) Adefovir accumulation and nephrotoxicity in renal interstitium: Role of organic anion transporters of kidney. Life Sci 224:41\u201350. https:\/\/doi.org\/10.1016\/j.lfs.2019.03.042","journal-title":"Life Sci"},{"key":"5466_CR15","unstructured":"Kc C (1999) Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. In: Clin. Pharmacokinet. https:\/\/antlia.med.unipmn.it:2146\/10092959\/. Accessed 21 Dec 2020"},{"key":"5466_CR16","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/j.1445-5994.2012.02854.x","volume":"42","author":"CL Dai","year":"2012","unstructured":"Dai CL, Zhu M, Wang BP et al (2012) Prolonged adefovir therapy associated Fanconi syndrome and interstitial nephritis in hepatitis B. Intern Med J 42:955\u2013957. https:\/\/doi.org\/10.1111\/j.1445-5994.2012.02854.x","journal-title":"Intern Med J"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-022-05466-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-022-05466-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-022-05466-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T03:16:15Z","timestamp":1656299775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-022-05466-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,22]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["5466"],"URL":"https:\/\/doi.org\/10.1007\/s00705-022-05466-y","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"type":"print","value":"0304-8608"},{"type":"electronic","value":"1432-8798"}],"subject":[],"published":{"date-parts":[[2022,5,22]]},"assertion":[{"value":"3 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was approved by our local ethics committee as protocol \u201cHBV-analogues\u201d on 15 May 2015. This study was approved by the local ethics committee as \u201cHBV-Analogues Study\u201d (Prot. N\u00b0002360; 26\/1\/2015), and all included subjects provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}